148 related articles for article (PubMed ID: 33622518)
1. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
4. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
Wadhwa V
J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-induced hypophysitis: review of the literature.
Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
9. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
10. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
11. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
12. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
[TBL] [Abstract][Full Text] [Related]
13. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
15. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
Singh D; Hsu CC; Kwan GN; Bhuta S
Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
[No Abstract] [Full Text] [Related]
17. Hyponatremia associated with Ipilimumab-induced hypophysitis.
Barnard ZR; Walcott BP; Kahle KT; Nahed BV; Coumans JV
Med Oncol; 2012 Mar; 29(1):374-7. PubMed ID: 21264545
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
[TBL] [Abstract][Full Text] [Related]
20. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
[Next] [New Search]